None listed
Conditions
Brief summary
This study aims to directly compare the laboratory findings from samples collected from 10 healthy volunteers with results from a laboratory bladder infection model, using similar antibiotic therapy dosing. Laboratory testing involves measuring concentrations of amoxicillin and clavulanate in urine, assessing the activity of the antibiotic against E. coli uropathogens, and studying how the antibiotic affect the healthy microorganisms in the urinary tract, called the urobiome. Results from this study will validate the utility of the laboratory bladder infection model and help guide future research. This includes finding the best doses of antibiotics and testing other types of antimicrobials.
Interventions
This cross-over study involves a total of four visits at The Alfred hospital (two visits for dosing stage 1, and two visits for dosing stage 2), and a phone calls as follow up after each dosing stage. We will collect the following information for the project from participants: - Age (years) - Measured height (cm) and weight (kg) - Normal daily exercise regimen - Nicotine intake - Normal daily diet and fluid intake - Prior UTI history: number of UTIs in the past year, severity of symptoms, treatments received, and any hospitalisation - Concurrent medications: within 7 days prior to dosing stage 1 and dosing stage 2 - Concurrent supplements (probiotics, phyto therapeutics, cranberry products, vitamins): within 7 days prior to stage 1 and stage 2 dosing); including prior use of supplements within the past 12 months. - Prior use of any other antimicrobials in the last 12-months - Adverse reactions and allergies: known allergies and previous use of amoxicillin-clavulanate. You will receive two oral amoxicillin-clavulanate regimens on two separate days, provided by the study doctor, with at least 7 days between the two dosing stages (wash-out period): - Dosing Stage 1 (standard full dose): Amoxicillin-clavulanate as a dose of 875 mg amoxicillin and 125 mg clavulanate, three doses (3 tablets), over 24 hours You will then have a wash-out period of at least 7 days to clear the antibiotic from your system, before you can start dosing stage 2 (see comparator section for dosing stage 2). For the first dosing stage, the first two antibiotic tablets will be administered on-site under direct observation by the study team, with the time of dosing recorded. The third tablet will be taken at home at the scheduled time. Participants will be provided only with the exact number of tablets required for the study, and dosing times will be documented to support adherence monitoring. Participants will be asked to collect full urine voids over specific time-intervals during the study period, and get several blood samples drawn by research nurses. You will be asked to record voids, fluid and diet intake on provided sheet during the study period. You will be asked to record all entries immediately after urinating, drinking or eating to ensure accuracy. The follow-up phone call will be conducted by a member of the study team and is expected to last approximately 5 to 10 minutes.
Sponsors
Study design
Eligibility
Inclusion criteria
To be eligible to participate in this pilot study, the individual must meet the following criteria: - Female - Age: 18 years or older - Can read English - Able to provide written informed consent
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: - Extremes in body weight range (BMI 30) - Pregnant or breastfeeding - Having difficulty swallowing pills / require crushing or chewing pills to swallow - Having other concurrent acute illness (e.g., COVID-19 or other febrile illness, etc.) - Medical history of diabetes - Medical history of kidney disease or stones - Symptoms of a urinary tract infection (e.g., pain on urination, increased frequency) - Difficulty urinating regularly - Taking antibiotics (either currently, or in the preceding 3 months) - Previously experienced liver problems after taking amoxicillin-clavulanate tablets or any other medicines - Taking other medication with drug interactions with amoxicillin-clavulanate: methotrexate, mycophenolate, medicines used to treat gout (for example allopurinol or probenecid), warfarin or other medicines used to prevent blood clots - Taking prescribed or over-the-counter diuretics - Allergy to amoxicillin trihydrate, potassium clavulanate, penicillin or similar types of antibiotics (such as cephalosporins), or any of the inactive ingredients (magnesium stearate, sodium starch glycollate, colloidal anhydrous silica, microcrystalline cellulose), or tablet coating (containing colouring agent titanium dioxide, hypromellose, propylene glycol, purified talc, and ethylcellulose)